UY33627A - Compuestos para tratar enfermedades neurodegenerativas - Google Patents

Compuestos para tratar enfermedades neurodegenerativas

Info

Publication number
UY33627A
UY33627A UY0001033627A UY33627A UY33627A UY 33627 A UY33627 A UY 33627A UY 0001033627 A UY0001033627 A UY 0001033627A UY 33627 A UY33627 A UY 33627A UY 33627 A UY33627 A UY 33627A
Authority
UY
Uruguay
Prior art keywords
compounds
neurodegenerative diseases
treat neurodegenerative
treat
página
Prior art date
Application number
UY0001033627A
Other languages
English (en)
Inventor
Kevin W Hunt
Tony P Tang
Allen A Thomas
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of UY33627A publication Critical patent/UY33627A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Abstract

La invención proporciona nuevos compuestos tricíclicos de la fórmula I´ que inhiben el clivaje de beta-secretasa de APP y son de utilidad como agentes terapéuticos para el tratamiento de enfermedades neurodegenerativas
UY0001033627A 2010-09-24 2011-09-23 Compuestos para tratar enfermedades neurodegenerativas UY33627A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38629610P 2010-09-24 2010-09-24

Publications (1)

Publication Number Publication Date
UY33627A true UY33627A (es) 2013-04-30

Family

ID=45874425

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033627A UY33627A (es) 2010-09-24 2011-09-23 Compuestos para tratar enfermedades neurodegenerativas

Country Status (5)

Country Link
US (1) US20120083501A1 (es)
AR (1) AR083169A1 (es)
TW (1) TW201219400A (es)
UY (1) UY33627A (es)
WO (1) WO2012040641A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121510A2 (en) 2005-05-09 2006-11-16 Theranos, Inc. Point-of-care fluidic systems and uses thereof
US8741230B2 (en) 2006-03-24 2014-06-03 Theranos, Inc. Systems and methods of sample processing and fluid control in a fluidic system
SG188082A1 (en) 2007-10-02 2013-03-28 Theranos Inc Modular point-of-care devices and uses thereof
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
EP2643325A1 (en) 2010-11-23 2013-10-02 Amgen Inc. Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
TWI690594B (zh) 2011-01-21 2020-04-11 美商賽瑞諾斯Ｉｐ有限責任公司 樣本使用最大化之系統及方法
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
EP2675810A1 (en) 2011-02-15 2013-12-25 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
EP2694489B1 (en) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2694521B1 (en) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
JP2014524472A (ja) 2011-08-22 2014-09-22 メルク・シャープ・アンド・ドーム・コーポレーション Ｂａｃｅ阻害剤としての２−スピロ置換イミノチアジンならびにそのモノオキシドおよびジオキシド、組成物、ならびにそれらの使用
US9268915B2 (en) 2011-09-25 2016-02-23 Theranos, Inc. Systems and methods for diagnosis or treatment
US8840838B2 (en) 2011-09-25 2014-09-23 Theranos, Inc. Centrifuge configurations
US9664702B2 (en) 2011-09-25 2017-05-30 Theranos, Inc. Fluid handling apparatus and configurations
US8475739B2 (en) 2011-09-25 2013-07-02 Theranos, Inc. Systems and methods for fluid handling
US9632102B2 (en) 2011-09-25 2017-04-25 Theranos, Inc. Systems and methods for multi-purpose analysis
US9619627B2 (en) 2011-09-25 2017-04-11 Theranos, Inc. Systems and methods for collecting and transmitting assay results
US20140170735A1 (en) 2011-09-25 2014-06-19 Elizabeth A. Holmes Systems and methods for multi-analysis
US8380541B1 (en) 2011-09-25 2013-02-19 Theranos, Inc. Systems and methods for collecting and transmitting assay results
US9296759B2 (en) 2011-09-21 2016-03-29 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US10012664B2 (en) 2011-09-25 2018-07-03 Theranos Ip Company, Llc Systems and methods for fluid and component handling
US9250229B2 (en) 2011-09-25 2016-02-02 Theranos, Inc. Systems and methods for multi-analysis
US9810704B2 (en) 2013-02-18 2017-11-07 Theranos, Inc. Systems and methods for multi-analysis
EP2780321B1 (en) 2011-10-10 2015-12-30 Astrazeneca AB Mono-fluoro beta-secretase inhibitors
AU2013267555A1 (en) 2012-05-30 2014-12-04 Comentis, Inc. Chromane compounds
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US10548882B2 (en) 2012-06-21 2020-02-04 Astrazeneca Ab Camsylate salt
WO2014078314A1 (en) 2012-11-15 2014-05-22 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
WO2019060720A1 (en) 2017-09-25 2019-03-28 Case Western Reserve University COMPOSITIONS AND METHODS FOR REDUCING SERUM CHOLESTEROL AND PCSK9
US11931339B2 (en) 2018-06-25 2024-03-19 Case Western Reserve University Compositions and methods for treating tissue injury
AU2019344066A1 (en) 2018-09-21 2021-04-22 Case Western Reserve University Aldoketo reductase inhibitors and uses thereof
WO2021061763A1 (en) * 2019-09-23 2021-04-01 Case Western Reserve University Aldoketo reductase inhibitors and uses thereof
US11932655B1 (en) 2023-10-17 2024-03-19 King Faisal University 12-bromo-2,16-dioxapentacyclo[7.7.5.01,21.03,8.010,15]henicosa3(8),10,12,14-tetraene-7,20-dione as an antimicrobial compound

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200730523A (en) * 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
WO2007100536A1 (en) * 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
EP2063889A4 (en) * 2006-09-07 2009-09-16 Merck & Co Inc SPIROPIPERIDINE BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE

Also Published As

Publication number Publication date
US20120083501A1 (en) 2012-04-05
AR083169A1 (es) 2013-02-06
WO2012040641A3 (en) 2012-06-07
TW201219400A (en) 2012-05-16
WO2012040641A2 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
UY33627A (es) Compuestos para tratar enfermedades neurodegenerativas
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
UY34503A (es) ?sal de bromhidrato de pridopidina?
UY34820A (es) Compuestos tipo pirrolo-pirrolidinona
UY34445A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
UY34156A (es) Compuestos inhibidores de metaloenzimas
UY34177A (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
UY34550A (es) Bencilpirazoles sustituidos
UY34145A (es) Compuestos inhibidores de metaloenzimas
UY34146A (es) Compuestos inhibidores de metaloenzimas
UY34817A (es) Tienopirimidinas
CL2012003385A1 (es) Tratamiento para la incontinencia.
UY34302A (es) COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2- AMINA
UY34591A (es) Compuestos de imidazopirrolidinona
UY34374A (es) Benzilindazoles sustituidos
UY34523A (es) Derivados de betulina
UY34037A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
UY34885A (es) Proteínas de unión anti-mesotelina
EA201400178A1 (ru) Лечение рака молочной железы
UY34648A (es) Amidas como inhibidores de pim
UY33925A (es) Inhibidores tricíclicos de quinasas
UY34467A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
UY33929A (es) Compuestos de ciclohexilo tetrasustituido como inhibidores de quinasas

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20140703